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‘‘Maintaining the Horizontal Line’’:
early intervention and prevention of CF lung diseaseThe pulmonary disease of Cystic Fibrosis (CF) is char-
acterized by periods of well-being with minimal symptoms
and functional stability, interspersed with acute episodes of
clinical deterioration (‘‘exacerbation’’) caused by blazing
endobronchial inflammation and bacterial growth, or
slower, smoldering episodes (‘‘sub-acute’’ or slow ‘‘exacer-
bation’’) of clinical and decline (Fig. 1).
Functionally, this cycle manifests itself by drops in lung
function from which the patient may either recover com-
pletely with therapy (‘‘return to the baseline’’). Or be left
with a permanent loss (‘‘lower baseline’’). This cycle which
results in progressive airways obstruction, parenchymal
destruction, disability and eventual demise, can only be
reverted, eventually, by a successful lung transplantation
(Fig. 2).
Medical interventions must be timely and aggressive, if
they are to arrest, delay or prevent the ineffable downward
spiral of deterioration. Prevention of irreversible damage is
the si ne qua non of CF management. The concept of early
intervention has become the ‘‘mantra’’ of clinicians caring
for individuals with CF. The constellation of therapies and
hygienic measures encompassed in such interventions
requires clear definition, guidelines for implementation,
and eventual measurement of outcomes to prove its efficacy.
Therapeutic programs must be adapted to specific geo-
graphical, social and political environments. The therapy of
CF is intrinsically expensive and complex, and will become
more so as new drugs are discovered. Poverty, ignorance,
geographic barriers among others factors, hamper access to
CF care. Lastly, therapeutic schemes must be individual-
ized—since no two patients with CF are identical—but
always within the framework of care guidelines such as
the ones offered in this issue of The Journal of Cystic
Fibrosis. Further, therapeutic schemes must be evaluated
over time by means of data gathering in national and
international registries, and periodic measurement of clinical
outcomes.
The earliest form of intervention, the most drastic (and
one that for many people represent a perverse approach to
the problem) is simply the avoidance of births of individuals
homozygous for CFTR mutations, or even individuals
carrying any known CFTR mutation. Pre-natal testing is
currently routinely offered to expectant mothers in the US.1569-1993/$ - see front matter D 2004 Published by Elsevier B.V. on behalf of E
doi:10.1016/j.jcf.2004.05.044Those found to carry known mutations of CFTR have their
husbands tested and—if they are also found to be carriers—
chorionic villous sampling or amniocentesis are recommen-
ded. In cases of donor eggs and sperm, the situation
becomes obviously more complicated, however, donor
screening is becoming prevalent. Decisions based on dis-
covery of mutated copies of CFTR in a fetus vary greatly
and run the gamut of human behavior, as described in this
European Consensus. These attitudes are based on religious,
social and emotional factors. Many parents of children with
CF choose not to undergo pre-natal testing, or do so only to
prepare themselves to care for a potential affected child,
without intention of terminating the pregnancy. Pre-natal
testing has already resulted in decreased rates of CF births in
some communities, however. To avoid a birth of an affected
offspring, some couples resort to methods such as such as
artificial insemination, in vitro fertilization and embryonic
biopsy, and others. The ultimate impact of all these inter-
ventions is still to be measured.
Gene transfer into affected embryos and fetuses, as a
form of early intervention and possible cure, is still in its
experimental phase; it is unclear to date if gene transfer at all
will be a successful therapeutic avenue; its prenatal use adds
complexity to this option, both from technical and philo-
sophical view points.
The impact of neonatal screening on the ultimate course
of the disease, as described in the accompanying document,
is still unclear. Long-term, longitudinal blind studies on the
impact of neonatal screening have become impossible, as
these programs are being instituted across the board. Long-
term epidemiological studies and eventual multivariate
analysis may cast some light, years from now, as to the
ultimate effect of neonatal screening on outcome. It is clear,
nevertheless, that neonatal screening may be important in
helping to ‘‘maintain the horizontal’’ insofar early identifi-
cation of patients results in improved nutrition, one of the
risk factors associated with deterioration of lung disease.
The effect on Pseudomonas infection is not evident, sug-
gesting that this risk factor may be more tightly linked to the
type of mutation carried by the affected individual.
The basic abnormality of CFTR renders the epithelium
prone to up-regulation of inflammation and favors bacterial
adherence. Newer investigational therapies such as proteinuropean Cystic Fibrosis Society.
Fig. 1. Diagrammatic representation of clinical course over time in Cystic
Fibrosis. Meconium ileum is the earliest event. Affected individuals can be
largely symptomatic or mildly symptomatic for variable periods of time
(solid line) or start becoming increasingly symptomatic earlier in life
(dotted line) and then suffer increasingly severe, frequent, and permanent
signs and symptoms of pulmonary disease until death.
Fig. 2. Diagrammatic representation of pulmonary function (PFT) over
time. Exacerbations of lung disease result in drops in PFT, which are
recoverable to ‘‘baseline’’ ‘‘The Horizontal’’ represents an ideal state of
stability and normality. Clinical exacerbations and progression of lung
disease lower the baseline progressively, until death or successful lung
transplantation is achieved.
Editorial64repair and alternative activation of ion channels appear to
hold promise in the ultimate control of the pathophysiologic
mechanisms that cause lung damage. To date, however,
clinicians do not count with commercially available weap-
ons of the kind, and must concentrate their efforts in
containing the risk factors known to be associated with a
downward course, and containing the cycle of infection–
inflammation known to result in eventual lung destruction.
Genotype-phenotype correlations are notoriously unpredict-
able when it applies to CF lung disease; although type I and
II mutations are known to be associated with worse lung
disease, meconium ileus, etc, any CF clinician can report,
for instance, on patients who are homozygous for the delta
y508 mutation, who have reached adulthood with minimal
lung disease and dysfunction. The effect of modifier genes
and other factors remains still a fertile ground for investi-
gation and a largely unknown field.
Thus, the management of CF, and early intervention and
prevention programs must center on known clinical factors
about which clinicians can exercise some control, for which
therapeutic approaches, albeit imperfect, are available.
The identification of risks factors for deterioration has
been the product of multivariate analyses of large databases.
These studies have highlighted the importance of the ongo-
ing acquisition of epidemiological data at regular intervals
into patient registries, whether these are regional, national or
even international. The variability of the disease and the
insertion of therapeutic agents over time demand that large
amounts of data are collected and analyzed over long periods
of time to assess efficacy and changes in clinical outcomes.
Some of the most important risk factors for deterioration
and poor survival include the acquisition of P. aeruginosa,
especially the mucoid form [1] (Fig. 3) and, later, multi-
resistant organisms, malnutrition, and pulmonary function
over time .Other factors include complications such as
diabetes and hepatic dysfunction among others.
The European community of CF caregivers has gained
distinction for its aggressive approach to the biology,detection and management of P. aeruginosa infection and
the attendant inflammation in CF. The consensus document
in this issue addresses this aspect of the disease in detail and
in a scholarly manner. The evidence to date indicates that
eradication of P. aeruginosa upon new acquisition should be
attempted as a means to delay permanent colonization and
infection. The issue that upon which there seems not to be
universal agreement is the degree of aggressiveness with
which the search for the microorganism should be under-
taken, e.g. the use of bronchoscopy and bronchial lavages.
The need to gain a better understanding of the infection
status of patients is tempered by the logistics and cost of
submitting patients to repeated invasive procedures. Should
genotype enter into the indication for such procedures, as P.
aeruginosa is more likely to be present in individuals with
types I and II mutations? Further investigation appears
warranted.
I should like to highlight the problematic nature of early
detection of inflammatory activity, which seems to occur
even in the absence of apparent infection. The lack of
adequate biological markers of inflammation leaves the
clinician bereft of means of detection of nascent or increas-
ing inflammatory activity, before the patients acknowledge
symptoms. Clinicians are rendered incapable of intercepting
the course at its onset or shortly thereafter. We are left to
obtain surrogate markers, such as clinical manifestations and
measurement of pulmonary function.
Pulmonary function is the single most important objec-
tive outcome criterion in the assessment of patient health
and the efficacy of interventions. The most frequently used
parameters are the spirometric measurements of flows at all
lung volumes and flow rates; little attention has been paid to
the value of measurement of residual value and RV/TLC
(residual volume over total lung capacity over time) due
perhaps to the fact that these measurements require a
Fig. 3. Survival by age against slope of decrease of flow rates. Steeper decreases result in decreased survival rate (adapted from Corey et al., J Pediatr 1997;
131:809–814, with permission).
Editorial 65complete laboratory and are more costly and complex to
obtain than spirometry data. The slope of deterioration over
time is more important as a prognostic factor than isolated
measurements [2,3]. Slow deterioration over time, or low,
steady values are less alarming than sudden or accelerated
loss of pulmonary function, which heralds uncontrolled
disease (Fig. 4) The aim of early and aggressive intervention
when confronted with any loss of lung function is to
‘‘restore the horizontal’’ and then ‘‘maintain the horizontal’’,
that is, bring the patient’s lung function to an optimum
baseline and maintain it, as a means to improve survival and
quality of life.
Periodic and regular measurements of PFT are an impor-
tant aid to early intervention and prevention of lung disease.
Similarly to a diabetic individual who measures his blood
glucose daily, or a labile hypertensive person who measures
his blood pressure, I would submit that daily spirometryFig. 4. Graphic representing the impact of Pseudomonas aeruginosa infection o
Pulmonol 1992;12:158–161; with permission from the publisher).should be incorporated in the regiment of individuals with
CF. Hand-held spirometers are already part of the daily
monitoring regimen of patients after lung transplantation;
we have used such devices in difficult to con troll asthmatics,
for instance. Newer technology, which allows for distance
monitoring with the use of tele-spirometry should improve
response time by clinicians to significant changes in patient’s
status. This would be especially useful in individuals who
enjoy good lung function, as their symptoms may not
become apparent to them until significant obstruction—as
measured by flow rates and timed volumes—is present.
The development of national and international registries
is essential to the understanding of the impact of biological
phenomenon on large populations. Registry items often
stem from consensus documents and guidelines like this
one and become and important source of assessment of
widespread interventions and practice patterns. The mainte-n survival of patients with CF (adapted from Henry, R.L. et al., Pediatr
Editorial66nance of these databases requires ongoing economic support
and attention.
The document in this issue of the Journal of Cystic
Fibrosis is an important hallmark for the European CF
community. The value of establishing guidelines via con-
sensus cannot be underestimated, especially when absolute
truths based on accurate scientific data are lacking. These
documents are not ‘‘recipes’’ for management, or attempts at
regulating or legislating therapy without giving physicians
the right to exercise their individual judgment (as some
corridor conversations would suggest). The recommenda-
tions contained therein are based on the best available
knowledge, and where this is incomplete, the best judgment
and combined wisdom of a group of experienced clinicians
and scientists. I had the privilege of chairing the first such
consensus conference in the US fifteen years ago, that
resulted in the US CF Foundation Guidelines for Patient
Services, Evaluation and Monitoring in CF Centers [4]. To
quote from the original document: ‘‘The aim of this guide-
line is to promote a uniform level of care and teaching
services at CF centers and to provide a general framework
for good patient care. The relevance to specific situations
will depend on the individual variation and clinical course
and professional judgment.’’
In sum, the basic philosophical tenet of management of
CF, in the absence of definitive methods of control (i.e.
cure) are the prevention of deterioration by modification or
elimination risk factors and the earliest possible interruption
of injurious processes. In the absence of biological markers
of early inflammatory activity and lung damage we are
forced to carefully follow clinical substitutes. Ongoing
surveillance of clinical status—a clinical ‘‘radar’’—would
help to provide signals indicating the need for therapeutic
intervention.
Finally, the issue of adherence by patients to therapeutic
regimens brings all considerations to a very practical
crossroad. Patient adherence to daily routines is the leastunderstood and controllable of all variables affecting
outcome. Neither the best therapeutic guidelines, enhanced
drug delivery systems, nor the most compulsive of care-
givers can prevent the damaging impact of behaviors that
are essentially self-damaging. The mounting complexities
of CF care and drug regimens runs counter to the desires
of people affected with CF to lead a normal life. This
ongoing struggle between ‘‘living right and doing what is
right’’ is a sobering reminder that until a real cure or
effective control of CF is achieved, which can be admin-
istered in an expeditious manner (and what a tall order this
is!!), we will be constantly humbled by human nature
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